Literature DB >> 15877049

An efficient construction of conditionally replicating adenoviruses that target tumor cells with multiple factors.

S Nagano1, H Oshika, H Fujiwara, S Komiya, K Kosai.   

Abstract

Despite the enormous potential of conditionally replicating adenoviruses (CRAs), the time-consuming and laborious methods required to construct CRAs have hampered both the development of CRAs that can specifically target tumors with multiple factors (m-CRA) and the efficient analysis of diverse candidate CRAs. Here, we present a novel method for efficiently constructing diverse m-CRAs. Elements involving viral replication, therapeutic genes, and adenoviral backbones were separately introduced into three plasmids of P1, P2, and P3, respectively, which comprised different antibiotic resistant genes, different ori, and a single loxP (H) sequence. Independently constructed plasmids were combined at 100% accuracy by transformation with originally prepared Cre and specific antibiotics in specific Escherichia coli; transfection of the resulting P1+2+3 plasmids into 293 cells efficiently generated m-CRAs. Moreover, the simultaneous generation of diverse m-CRAs was achieved at 100% accuracy by handling diverse types of P1+2 and P3. Alternatively, co-transfection of P1+3 and P2 plasmids into Cre-expressing 293 cells directly generated m-CRA with therapeutic genes. Thus, our three-plasmid system, which allows unrestricted construction and efficient fusion of individual elements, should expedite the process of generating, modifying, and testing diverse m-CRAs for the development of the ideal m-CRA for tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877049     DOI: 10.1038/sj.gt.3302540

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

Review 1.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

2.  FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure.

Authors:  Shinjiro Hino; Akihisa Sakamoto; Katsuya Nagaoka; Kotaro Anan; Yuqing Wang; Shinya Mimasu; Takashi Umehara; Shigeyuki Yokoyama; Ken-Ichiro Kosai; Mitsuyoshi Nakao
Journal:  Nat Commun       Date:  2012-03-27       Impact factor: 14.919

Review 3.  Viral Vector-Based Innovative Approaches to Directly Abolishing Tumorigenic Pluripotent Stem Cells for Safer Regenerative Medicine.

Authors:  Kaoru Mitsui; Kanako Ide; Tomoyuki Takahashi; Ken-Ichiro Kosai
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

Review 4.  Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy.

Authors:  Maki Watanabe; Yuya Nishikawaji; Hirotaka Kawakami; Ken-Ichiro Kosai
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

5.  Inducible caspase-9 suicide gene under control of endogenous oct4 to safeguard mouse and human pluripotent stem cell therapy.

Authors:  Yang Liu; Yang Yang; Yangyang Suo; Chuan Li; Min Chen; Shuwen Zheng; Hao Li; Chengcheng Tang; Nana Fan; Ting Lan; Jizeng Zhou; Yingying Li; Jiaowei Wang; Huangyao Chen; Qingjian Zou; Liangxue Lai
Journal:  Mol Ther Methods Clin Dev       Date:  2022-02-01       Impact factor: 6.698

6.  Conditionally replicating adenovirus prevents pluripotent stem cell-derived teratoma by specifically eliminating undifferentiated cells.

Authors:  Kaoru Mitsui; Kanako Ide; Akiko Takayama; Tadahisa Wada; Rie Irie; Ken-Ichiro Kosai
Journal:  Mol Ther Methods Clin Dev       Date:  2015-08-12       Impact factor: 6.698

7.  Survivin-responsive conditionally replicating adenovirus kills rhabdomyosarcoma stem cells more efficiently than their progeny.

Authors:  Kiyonori Tanoue; Yuqing Wang; Minako Ikeda; Kaoru Mitsui; Rie Irie; Takao Setoguchi; Setsuro Komiya; Shoji Natsugoe; Ken-Ichiro Kosai
Journal:  J Transl Med       Date:  2014-01-27       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.